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Intermediate a,-antitrypsin deficiency PiSZ: a risk 
factor for pulmonary emphysema? 
N. SEERSHOLM AND A. KOK-JENSEN 
Bispebjerg Hospital, Department of Respiratory Medic&, Copenhagen, Denmark 
It is well documented that the severe hereditary disorder a,-antitrypsin deficiency (alATD) PiZZ is a strong risk 
factor for emphysema, especially among smokers, but the role of intermediate alATD PiMZ and PiSZ in the 
development of emphysema remains uncertain. 
In this study, we have evaluated mortality and lung function of 94 persons with intermediate alATD PiSZ of 
whom 66 were non-index cases, i.e. persons ascertained through family studies. 
The index cases and the non-index cases were similar with respect to sex, age and follow-up time, but differed in 
smoking habits and FEV,. Among the smokers there was no significant difference in pack-years between index cases 
and non-index cases. The overall Standardized Mortality Ratio (SMR) was 1.6 (95% confidence intervals (CI): 
0.8-2.7). For the index cases the SMR was 4.3 (95% CI: 198.5) and for the non-index cases it was 0.8 (95% CI: 
0.331.8). In the index group six patients died of pulmonary emphysema, one of pulmonary fibrosis, and one of colon 
cancer. In the non-index group two died of pulmonary emphysema, two of pneumonia, and one of cerebral 
haemorrhage. The mean initial FEV,% predicted among the index cases was 59% compared with 94% among the 
non-index cases. 
Based on the analysis of the non-index cases it is concluded that only a small fraction of persons with the PiSZ 
phenotype are at increased risk of developing pulmonary emphysema, and at an older age than persons with the PiZ 
phenotype. 
RESPIR. MED. (1998) 92, 241-245 
Introduction 
a,-Antitrypsin exists in over 100 biochemical genetic 
variants - the protease inhibitor system (Pi) which is inher- 
ited in an autosomal recessive pattern with codominant 
alleles (1). Epidemiologically, the most important Pi types 
are M, S and Z. Homozygotes of the deficient type Z have 
only lo-20% of the normal serum concentration of the 
inhibitor and are at high risk of developing emphysema 
(2,3). Patients with the heterozygote form PiSZ have serum 
antitrypsin (AT) concentrations of around 40% of the 
normal value (4). 
Unlike persons with severe alATD PiZ, it is uncertain 
whether persons with PiSZ are at increased risk of lung 
disease. Only a few papers have dealt with the epidemiology 
of PiSZ persons; the most comprehensive study was carried 
out in 1983 when Hutchinson and colleagues examined 25 
cases, of whom 14 were index-cases - i.e. persons diagnosed 
because of pulmonary symptoms. The conclusion was that 
the SZ phenotype was of much less importance than the Z 
phenotype in the development of emphysema (5). 
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The main problems with studies of a rare disease 
such as alATD is to get a sufficient number of patients and 
to find patients who are not subject to ascertainment 
bias, i.e. patients not identified because of symptoms. 
The purpose of the present paper was to evaluate 
mortality and morbidity in 94 persons with alATD 
PiSZ. Two-thirds of the patients were identified 
through family studies and were thus less subject to 
ascertainment bias. 
Patients and Methods 
Persons with PiSZ were identified through the files of the 
Danish a,-Antitrypsin Deficiency Register. Since 1978 
patients with alATD PiZ and PiSZ have been reported by 
physicians throughout Denmark. Once a patient is regis- 
tered a family record is obtained and relatives at risk of 
having a Z-gene are offered an examination of their Pi-type. 
Thus, the register contains subjects ascertained because of 
respiratory symptoms (index cases) as well as subjects 
ascertained through family studies who do not necessarily 
have any pulmonary problems (non-index cases). More 
than 3500 family members of index cases have been tested, 
and by 31 December 1995 the register contained 698 
persons with severe alATD of whom 387 were index cases 
and 311 non-index cases. 
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TABLE 1. Demographic data of the 94 study subjects by index cases and non-index cases 
Index cases Non-index cases All persons 
n 
Deaths 
Age at diagnosis (years, mean (range)) 
Follow up time (years, mean (range)) 
Sex 
Males (%) 
Smoking history 
Current smokers 
Former smokers 
Never smokers 
Unknown 
Pack-years 
Mean (range) 
a,-Antitrypsin concentration 
Cum011 ~ ‘, mean (range)) 
28 (30%) 
8 
51 (20-73) 
53 (0.3-13) 
50 
6 (21%) 
11 (39%) 
10 (36%) 
1 (4%) 
29.8 (10-46) 
18.0 (8-27) 
66 (70%) 
5 
45 (20 78) 
6.3 (0.2-13) 
50 
21 (33%) 
9 (14%) 
23 (38%) 
10 (15%) 
27.2 (l-89) 
19.4 (1 l-34) 
94 (100%) 
13 
47 (20-78) 
6.0 (0.2-13) 
50 
26 (30%) 
20 (21%) 
33 (37%) 
10 (12%) 
28.1 (l-89) 
18.9 (8-34) 
Determination of a,-antitrypsin Pi type has been 
performed by the Department of Clinical Chemistry at 
Bispebjerg Hospital by isoelectric focusing as described by 
Fagerhol and Cox (6). 
For the index cases, lung function measurements 
(spirometry) were reported by the referring physician. 
When the non-index cases were ascertained they were 
encouraged to contact their general practitioner for 
measurement of lung function. Measurements were per- 
formed in accordance with European recommendations (7). 
Predicted values of FEV, were calculated according to 
European reference tables (8). For this study the first 
spirometry after the patient entered the register was used. 
Death certificates which provided information on date 
and cause of death were obtained from the Danish National 
Board of Health. 
Smoking status was defined as follows. A smoker was a 
person who had smoked at least 20 packs of cigarettes or at 
least one cigarette per day for at least 1 yr in a lifetime (9). 
An ex-smoker was a person who had abstained from 
smoking for at least 3 months. Pack-years was calculated by 
multiplying the years of smoking with the daily cigarette 
consumption divided by 20. 
Persons eligible for the present study were identified as 
Pi-type SZ with known vital status (i.e. dead, alive or 
emigrated) at the closing date of the study (31 December 
1995). Of the 698 patients in the register 97 had the PiSZ 
phenotype. Three of these were excluded because they did 
not reach the age 20 years during the study period, leaving 
94 subjects for study. 
STATISTICS 
The period of follow-up for survival calculation was taken 
from the date of entry into the register or age 20 years for 
persons who entered at a younger age, to the date of death, 
emigration, or 31 December 1995, whichever came first 
(10). Age, calendar time and sex specific standardized 
mortality rates (SMR) were calculated from the Danish 
reference tables published every year (11). Cox proportional 
hazards regression model was used to analyse difference in 
survival between index cases and non-index cases with 
control for the confounders sex and smoking habits (12). 
The t-test was used to evaluate differences in age, FEV, and 
follow-up time. 
Results 
The 94 persons with Pi-type SZ included 28 (30%) index 
cases and 66 (70%) non-index cases and, altogether, 567 
person-years were cumulated. Table 1 shows demographic 
data for the study population and for index cases and 
non-index cases separately. There was an equal proportion 
of males and females in the whole study population as well 
as in the two study groups separately. The mean age at 
entry in the study was 47 years (s~=17) and the mean 
follow-up time was 6.0 years (s~=4.0). There was no 
significant difference in age or follow-up time between index 
cases and non-index cases. For the patients with known 
smoking history, there was an equal percentage of never- 
smokers in the index and the non-index groups, but in the 
index group there were significantly more ex-smokers 
(P=O.O4). The mean serum a,-antitrypsin concentration 
was 19pmoll- ’ (~~=4.6) with no significant difference 
between index cases and non-index cases. 
During the follow-up period 13 persons died, with 8.2 
expected, yielding an SMR of 1.6 (95% CI: 0.8-2.7). Eight 
index cases died, giving a significantly elevated SMR of 
4.3 (95% CI: 1.998.5), compared with five deaths in the 
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TABLE 2. Causes of death for the 13 deceased patients 
Sex Age at death Cause of death 
Index cases 
Male 
Male 
Female 
Female 
,, Male 
Female 
Female 
Female 
Non-index cases 
Male 
Female 
Male 
Female 
Male 
45 Pulmonary emphysema 
58 Pulmonary emphysema 
61 Pulmonary emphysema 
61 Pulmonary emphysema 
69 Pulmonary emphysema 
IO Pulmonary emphysema 
66 Pulmonary fibrosis 
74 Colon cancer 
65 Pulmonary emphysema 
13 Pulmonary emphysema 
II Pneumonia 
87 Pneumonia 
19 Cerebral haemorrhage 
TABLE 3. FEV,% predicted, number of persons with FEV,% predicted G’5%, and FEV,IFVC ratio 
for index cases and non-index cases separately stratified by smoking habits 
Index cases 
(n=24) 
Non-index cases 
(n=41) 
All persons 
(n=65) 
FEV,% predicted at diagnosis mean (SD)* 
All persons 58.5 (32) 94.1(23) 
Ever smokers 50.1 (26) 89.9 (25) 
Never smokers 15,4 (39) 105 (18) 
Number (%) of persons with FEV,% predicted ~75% at diagnosis* 
All persons 14 (58%) 4 (10%) 
Ever smokers 10 (71%) 4 (18%) 
Never smokers 4 (57%) 0 
FEV,FVC, mean (SD)* 
All persons 0.53 (0.20) 0.77 (0.14) 
Ever smokers 0.47 (0.20) 0.76 (0.15) 
Never smokers 0.64 (0.14) 0.84 (0.07) 
81.4 (32) 
73.1 (32) 
94.1 (30) 
28 (43%) 
14 (39%) 
4 (18%) 
0.68 (0.20) 
0.64 (0.22) 
0.77 (0.13) 
*P<O.OOl for difference between index cases and non-index cases. 
non-index group (SMR=0.8; 95% CI: 0.3-1.8). Mean age at 
death for the eight index cases who died was 65 years 
compared with 77 years for the non-index cases (P=O.O4). 
The SMR of ever-smokers was 1.6 (95% CI: 0.6-3.3) and 
for never-smokers the SMR was also 1.6 (95% CI: 0.34.6). 
In Table 2 the causes of death are listed for index cases and 
non-index cases separately. 
For further analysis of the difference in survival between 
index cases and non-index cases with control for smoking 
habits, a Cox Proportional Hazards Regression model was 
fitted to the data. Age was used as the time variable, and 
sex, smoking habits and mode of ascertainment entered as 
covariates. Four dummy variables were created: a variable 
coded 1 for males and 0 for females, a variable coded 1 for 
ever-smokers and 0 otherwise, a variable coded 1 for 
unknown smoking history and 0 otherwise, and a variable 
coded 1 for index cases and 0 for non-index cases. The 
relative risk of death of the index cases compared with 
non-index cases, and controlling for sex and smoking 
habits, was 18 (95% CI: 1.9-171). A history of smoking was 
not associated with a significant increase of death (relative 
risk 1.0; 95% CI: 0.2-5.8) nor was there any significant 
inlluence of the other confounders. Due to the small 
number of events it was not possible to test for interaction 
between smoking habits and mode of ascertainment. 
Spirometry was available for 65 (69%) persons 24 (86%) 
index cases and 41 (62%) non-index cases) (Table 3). The 
mean FEV,% predicted at time of diagnosis was 81%. For 
the index cases it was 59%, which was significantly lower 
compared with 94% for the non-index cases (P<O.OOl). The 
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mean FEV,% predicted at diagnosis among ever-smokers 
was 73% compared with 94% among never-smokers 
(P<O.OS). In the group of non-index ever-smokers the mean 
FEV,% predicted was 90% compared with 105% among the 
non-index never-smokers (P=O.O54). 
A measure of the degree of pulmonary obstruction is the 
ratio of FEV, to FVC. Overall, the FEV,/FVC ratio was 
0.68 (Table 3). There was a highly significant difference 
between index cases and non-index cases as well as between 
ever-smokers and never-smokers. In both the index group 
and the non-index group there was a significant difference 
between ever-smokers and never-smokers. Non-index cases 
never-smokers had a mean FEV,IFVC ratio above 0.80, 
which is considered normal, and only four had an FEV,/ 
FVC ratio under 0.80. 
Discussion 
In this study of 94 PiSZ persons it was shown that index 
cases had a reduced survival compared to the survival of the 
general population. However, the index cases differed sig- 
nificantly from the non-index cases with respect to FEV,% 
predicted at diagnosis and smoking habits, but among the 
smokers there was no significant difference in pack-years. 
The difference in smoking habits was controlled for in the 
Cox regression model and yet the relative risk of death for 
index cases was 18, but with very wide confidence intervals. 
The possibilities for analysis of details were limited by the 
small number of persons and particularly the small number 
of deaths which prevented testing for interactions. 
Although the mortality of the non-index cases was not 
significantly increased, two out of five deaths were due to 
pulmonary emphysema and another two due to pneumonia 
which may have been caused by impaired lung function. 
This suggests that the PiSZ persons are at risk of developing 
lung disease, but so late in life that it is not reflected in the 
mortality analysis. We have previously reported survival 
analysis of the PiZ persons (13) and found median ages at 
death of 49 years and 69 years for the index cases and 
non-index cases respectively. Similar analysis of the PiSZ 
persons revealed a median age at death of 68 years for the 
index cases and 75 years for the non-index cases. 
Since the index cases were identified because they had 
pulmonary symptoms it is not surprising that they had 
increased mortality. It is more interesting that the non- 
index cases who were comparable with the index cases in 
terms of age, sex, life-time tobacco consumption and serum 
a,-antitrypsin did not have increased mortality. The ideal 
mortality study would be identification of PiSZ subjects 
through a large population screening, and two or three 
decades of follow-up. In this way selection bias would be 
avoided, but such a study is almost impossible. By including 
a large number of non-index cases in the present study we 
have, to some extent, avoided selection bias. 
In persons with al ATD PiZZ a highly variable survival 
has also been found regardless of smoking history, and it is 
probable that both in PiZZ and PiSZ patients other factors 
contribute to premature death (13). Ever-smokers and 
never-smokers had similar SMR, which most probably was 
due to selection bias, because some of the never-smokers 
were index cases and thus found because of pulmonary 
symptoms. 
It is well known that reduced FEV, is a very strong risk 
factor for mortality. Spirometry was available for only 69% 
of the subjects, but there was a significant difference in 
FEV, between index cases and non-index cases. Between 
smokers and never-smokers there was also a significant 
difference in FEV, but it was much less pronounced. The 
large proportion of missing spirometry data for the non- 
index cases is a problem that is difficult to overcome. The 
subjects were asked several times to contact their general 
practitioner for spirometry. It is possible that subjects 
without spirometry did not have pulmonary symptoms and 
it is likely that they would contact their general physician or 
the chest clinic if they had symptoms. We think therefore 
that the spirometries available in this study underestimate 
the presence of bronchial obstruction. 
Studies of COPD and protease inhibitor phenotypes have 
shown an increased prevalence of patients with deficient 
type PiZ and possibly the heterozygote type PiMZ (1417). 
Persons with PiSZ have a lower a,-antitrypsin concen- 
tration in the blood than do persons with PiMZ, so PiSZ 
might be a risk factor for COPD. 
The prevalence of the Z-gene and the S-gene in Denmark 
is similar, with frequencies of 0.023 and 0.022 respectively. 
In a screening of 200 000 newborns in Sweden the hetero- 
zygote form of a,-antitrypsin deficiency PiSZ was found in 
49 newborns, giving a prevalence of 0.025%, and the 
homozygote form PiZZ was found in 120, a prevalence of 
0.06% equivalent to a Z-gene frequency of 0.025 (18). 
However, only children with a,-antitrypsin concentration 
less than 40% of normal were genotyped, and some PiSZ 
children may have had higher concentrations and thus 
avoided testing. Therefore, the Z and S-gene frequencies in 
Denmark and Sweden are probably the same. The preva- 
lence of PiSZ has in other studies been found to be ten times 
the prevalence of PiZ (5,18). Some of this discrepancy can 
be explained in terms of difference in prevalence of the Z 
and S genes in different countries. The number of patients 
with a,-ATD PiSZ known to us is considerably smaller 
than what would be expected and smaller than the number 
of known PiZ patients. There are two feasible explanations 
for this difference in number of persons with PiZ and PiSZ 
held in the register: (1) the S-gene is not followed in family 
studies and the phenotype is not always investigated in 
persons with moderately reduced a-antitrypsin concen- 
tration, identifying a smaller proportion of SZ-persons than 
actually present, and (2) it is conceivable that the majority 
of PiSZ persons do not develop significant emphysema or 
that the PiSZ persons who develop emphysema are older at 
diagnosis and therefore not tested for a,-antitrypsin 
deficiency. 
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